SCHEMBL2385652

SCHEMBL2385652

CNCc1cccc(-c2cc3c4cc(C)ccc4[nH]c3n(C)c2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 1/20 0.38
▸ MAP2K4 P45985 1/20 0.38
▸ MDH2 P40926 1/20 0.38
▸ KDM4E B2RXH2 6/20 0.37
▸ ALDH1A1 P00352 5/20 0.37
▸ MAPT P10636 4/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ PRMT6 Q96LA8 2/20 0.37
▸ HPGD P15428 4/20 0.36
▸ HSD17B10 Q99714 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2381235 0.87 MAP2K4 (0.52) MAP2K4MDH2KDM4EALDH1A1MAPT
SCHEMBL3867849 0.82 KDM4E (0.50) MDH2KDM4EALDH1A1MAPTHPGD
SCHEMBL2385245 0.81 MAOB (0.41) MDH2KDM4EALDH1A1MAPTHPGD
SCHEMBL2384517 0.81 BRD4 (0.46) KDM4EALDH1A1MAPTBRD4HPGD
SCHEMBL2385299 0.80 KDM4E (0.38) MDH2KDM4EALDH1A1MAPTBRD4
SCHEMBL2383348 0.79 KIF11 (0.49) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL2383697 0.79 KDM4E (0.46) MAP2K4KDM4EALDH1A1MAPTHPGD
SCHEMBL2382889 0.79 KIF11 (0.45) MAP2K4KDM4EALDH1A1MAPTBRD4
SCHEMBL2385260 0.78 ASH1L (0.41) MAP2K4KDM4EALDH1A1MAPTHPGD
SCHEMBL2383613 0.78 ALDH1A1 (0.41) MDH2KDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012991-B2 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate SANOFI-AVENTIS (FR) 2011-09-06 — — US disclosed
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2008-09-04 — — US disclosed
US-7390818-B2 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-06-24 — — US disclosed
EP-1556382-B1 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-05-28 — — EP disclosed
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2005-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics PNPO, PDXK, PLPBP HTR7 839/4885MAP2K4 3236/4885MDH2 346/4885
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics PNPO, PLPBP, DPYD HTR7 985/4885MAP2K4 3730/4885MDH2 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback